Literature DB >> 16816777

Clinical assessment of suicide risk in depressive disorder.

William H Coryell1.   

Abstract

Efforts to identify clinical risk factors for complete suicide through the follow-up of depressed patients have yielded relatively few robust predictors. Those identified by at least three studies are (in order of decreasing frequency) suicidal plans/attempts, male sex, being single or living alone, inpatient status, and hopelessness. Because the best established of these predictors has only modest sensitivity and specificity, the need for other robust tools is clear. A rich body of research has identified two biological risk factors for suicide in depressive disorder: hypothalamic-pituitary-adrenal axis hyperactivity and deficits in serotonin function. Moreover, there is now considerable evidence that the dexamethasone suppression test and measures of serum cholesterol concentrations, respectively, may provide a clinically useful reflection of these two mechanisms. Observations that these measures appear to be additive, both with each other and with other clinical risk factors, indicate that a substantial improvement in the clinician's ability to assess suicide risk is possible.

Entities:  

Mesh:

Year:  2006        PMID: 16816777     DOI: 10.1017/s109285290001467x

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  6 in total

Review 1.  The hypothalamic-pituitary-adrenal axis and serotonin abnormalities: a selective overview for the implications of suicide prevention.

Authors:  Maurizio Pompili; Gianluca Serafini; Marco Innamorati; Anne Maria Möller-Leimkühler; Giancarlo Giupponi; Paolo Girardi; Roberto Tatarelli; David Lester
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-02-20       Impact factor: 5.270

2.  Suicidal behavior in prodromal Huntington disease.

Authors:  Jess G Fiedorowicz; James A Mills; Adam Ruggle; Douglas Langbehn; Jane S Paulsen
Journal:  Neurodegener Dis       Date:  2011-06-09       Impact factor: 2.977

3.  Reinforcement of Self-Regulated Brain Activity in Schizophrenia Patients Undergoing Rehabilitation.

Authors:  Renata Markiewicz; Beata Dobrowolska
Journal:  Biomed Res Int       Date:  2021-03-26       Impact factor: 3.411

4.  Improving Clinical, Cognitive, and Psychosocial Dysfunctions in Patients with Schizophrenia: A Neurofeedback Randomized Control Trial.

Authors:  Renata Markiewicz; Agnieszka Markiewicz-Gospodarek; Beata Dobrowolska; Bartosz Łoza
Journal:  Neural Plast       Date:  2021-08-12       Impact factor: 3.599

5.  Risk factors for suicidal attempt in patients with the melancholic subtype of depressive disorder: Implication for nursing care.

Authors:  Pengfei Xu; Ying Sun
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

6.  Initial Results of Tests Using GSR Biofeedback as a New Neurorehabilitation Technology Complementing Pharmacological Treatment of Patients with Schizophrenia.

Authors:  Renata Markiewicz; Beata Dobrowolska
Journal:  Biomed Res Int       Date:  2021-06-10       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.